Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
4 papers
Recent·Most cited
C. Jing, N. Prutsch, S. He…·A. T. W. Look
This study identifies XPO1 inhibitors as selective killers of TET2-mutant HSPCs and AML cells through apoptosis, without DNA damage.
M. H. Uddin, A. Aboukameel, Y. Li…·A. S. Azmi
This study investigates the synergy between XPO1 inhibitor selinexor and gemcitabine-nab-paclitaxel in pancreatic cancer using cellular and mouse models, showing improved survival and molecular changes.
H. Y. Khan, M. Nagasaka, Y. Li…·A. S. Azmi
This paper shows that combining XPO1 inhibitor selinexor with KRAS G12C inhibitors enhances antitumor effects in preclinical models of KRAS G12C mutant cancers.
G. Pianigiani, A. Gagliardi, F. Mezzasoma…·L. Brunetti
This study shows that prolonged XPO1 inhibition is more effective than intermittent dosing in NPM1-mutated AML by achieving stable HOX downregulation and anti-leukemic activity.